Crowd Funding Campaign launched on Capital Cell
Join the movement and help bringing affordable and high quality rehabilitation to people with gait impairment.
Every year, more than 15 million people suffer a stroke. For almost half of them, walking again stops being spontaneous and becomes a daily challenge.
The human brain can relearn and restore our motor skills, but today’s rehabilitation system doesn’t allow it. After just a few weeks in the hospital, most patients lose access to the intensive therapy they need. No follow-up, no continuity, no real recovery options.
The result: millions of people trapped in avoidable disability, with enormous emotional, social, and economic consequences.
That’s why Autonomyo was born. A Swiss company bringing robotic gait rehabilitation from the hospital to the homes. Its mission is clear: to restore independence to people with neurological disorder through safe, affordable, and clinically validated tehcnology.
Two devices to improve rehabilitation
Skywalk is a mechanical body-weight support system that ensures stability and fall protection during gait training.
NeuroXO is a wearable exoskeleton that interprets the patient’s intention in real time and adapts the level of assistance required for each movement.
Autonomyo has launched a €2.15M seed round, with an initial tranche of €550,000 to bring Skywalk to market, generate early revenues, and complete clinical validation and CE/FDA certification through Capital Cell. The round already includes €159,600 from founders and experienced angel investors, with institutional participation expected in the next phases. With €1.25M already committed through letters of intent, Autonomyo aims to close the full round in Q1 2026 and targets an exit by 2030.
Join the round: https://capitalcell.com/campaign/autonomyo/